Fujimoto, Ayataka
Qin, Bing
Bourikas, Dimitrios
Dickson, Najla
Moseley, Brian https://orcid.org/0000-0001-8573-7340
Sano, Tomonobu
Soma, Tadaharu
Sun, Weiwei
Watanabe, Jun https://orcid.org/0000-0002-4575-9358
Zhou, Dong
Inoue, Yushi
Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety, Tolerability, and Efficacy of Adjunctive Brivaracetam in Japanese and Chinese Patients with Focal-Onset Seizures: Interim Analysis of a Phase 3 Open-Label Extension Trial
https://doi.org/10.1007/s12325-025-03253-0
Funding for this research was provided by:
UCB
Article History
Received: 12 March 2025
Accepted: 19 May 2025
First Online: 23 June 2025
Declarations
:
: Ayataka Fujimoto was affiliated with Seirei Hamamatsu General Hospital, Shizuoka, Japan at the time the trial was conducted and is now affiliated with Dokkyo Medical University, Mibu, Japan; has received honoraria from Eisai, Novartis Pharmaceuticals, and UCB Japan, and has received research funds from Nobelpharma. Bing Qin, Dong Zhou and Yushi Inoue have no conflicts of interest. Dimitrios Bourikas, Najla Dickson, Brian Moseley, and Tomonobu Sano are salaried employees of UCB and receive stock or stock options from their employment. Tadaharu Soma, Weiwei Sun and Jun Watanabe are salaried employees of UCB.
: Patients’ informed consent was obtained and documented before trial participation. The trial protocol, amendments, and trial patient informed consent were reviewed and approved by a national, regional, or independent ethics committee or institutional review board. This trial was conducted in accordance with the current version of the applicable regulatory requirements, Japan’s Good Clinical Practice requirements, International Council for Harmonisation Good Clinical Practice requirements, the ethical principles that have their origin in the principles of the Declaration of Helsinki, and the local laws of the countries involved.